Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay - PubMed (original) (raw)

Comparative Study

Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay

A V Herz et al. Proc Natl Acad Sci U S A. 1996.

Abstract

Anti-viral drug treatment of human immunodeficiency virus type I (HIV-1) and hepatitis B virus (HBV) infections causes rapid reduction in plasma virus load. Viral decline occurs in several phases and provides information on important kinetic constants of virus replication in vivo and pharmacodynamical properties. We develop a mathematical model that takes into account the intracellular phase of the viral life-cycle, defined as the time between infection of a cell and production of new virus particles. We derive analytic solutions for the dynamics following treatment with reverse transcriptase inhibitors, protease inhibitors, or a combination of both. For HIV-1, our results show that the phase of rapid decay in plasma virus (days 2-7) allows precise estimates for the turnover rate of productively infected cells. The initial quasi-stationary phase (days 0-1) and the transition phase (days 1-2) are explained by the combined effects of pharmacological and intracellular delays, the clearance of free virus particles, and the decay of infected cells. Reliable estimates of the first three quantities are not possible from data on virus load only; such estimates require additional measurements. In contrast with HIV-1, for HBV our model predicts that frequent early sampling of plasma virus will lead to reliable estimates of the free virus half-life and the pharmacological properties of the administered drug. On the other hand, for HBV the half-life of infected cells cannot be estimated from plasma virus decay.

PubMed Disclaimer

Cited by

Implications of decoupling the intracellular and extracellular levels in multi-level models of virus growth.
Haseltine EL, Yin J, Rawlings JB. Haseltine EL, et al. Biotechnol Bioeng. 2008 Nov 1;101(4):811-20. doi: 10.1002/bit.21931. Biotechnol Bioeng. 2008. PMID: 18512261 Free PMC article.
Modeling the within-host dynamics of HIV infection.
Perelson AS, Ribeiro RM. Perelson AS, et al. BMC Biol. 2013 Sep 3;11:96. doi: 10.1186/1741-7007-11-96. BMC Biol. 2013. PMID: 24020860 Free PMC article. Review.
Phenotypic flux: The role of physiology in explaining the conundrum of bacterial persistence amid phage attack.
Igler C. Igler C. Virus Evol. 2022 Sep 15;8(2):veac086. doi: 10.1093/ve/veac086. eCollection 2022. Virus Evol. 2022. PMID: 36225237 Free PMC article. Review.
Incorporating Intracellular Processes in Virus Dynamics Models.
Ciupe SM, Conway JM. Ciupe SM, et al. Microorganisms. 2024 Apr 30;12(5):900. doi: 10.3390/microorganisms12050900. Microorganisms. 2024. PMID: 38792730 Free PMC article. Review.
Modeling within-host HIV-1 dynamics and the evolution of drug resistance: trade-offs between viral enzyme function and drug susceptibility.
Rong L, Gilchrist MA, Feng Z, Perelson AS. Rong L, et al. J Theor Biol. 2007 Aug 21;247(4):804-18. doi: 10.1016/j.jtbi.2007.04.014. Epub 2007 Apr 19. J Theor Biol. 2007. PMID: 17532343 Free PMC article.

References

1. Science. 1996 Mar 15;271(5255):1582-6 - PubMed
1. J Infect Dis. 1995 Jun;171(6):1411-9 - PubMed
1. AIDS. 1995;9 Suppl A:S183-92 - PubMed
1. Science. 1989 Mar 31;243(4899):1731-4 - PubMed
1. J Theor Biol. 1991 Jul 7;151(1):1-40 - PubMed

Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay - PubMed (original) (raw)